Namilumab
As of the edition of 20 October 2026, Namilumab is an antibody: stopped in 2025; acts on CSF2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2025
- Kind
- Antibody
- Registered trials
- 7, 2 stopped early
- Disease areas
- Immune system; Bones, joints and muscles; Blood and lymph; Skin and connective tissue; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of Namilumab.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CSF2 | Granulocyte-macrophage colony-stimulating factor | P04141 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 5 | 3 | 0 | 2 |
| All trials | 7 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Takeda | Lead sponsor of trials | 2011 to now |
| Izana Bioscience | Lead sponsor of trials | 2018 to now |
| Kinevant Sciences | Lead sponsor of trials | 2022 to now |